Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
03 04 2023
Historique:
medline: 18 4 2023
entrez: 14 4 2023
pubmed: 15 4 2023
Statut: ppublish

Résumé

The purpose of this study was to evaluate rod-mediated function with two-color dark-adapted perimetry (2cDAP) in patients with RPE65-related retinopathy treated with voretigene neparvovec-rzyl. Following dilation and dark adaptation, 2cDAP and FST were performed. The 2cDAP was measured on an Octopus 900 perimeter (Haag-Streit) with cyan (500 nm wavelength) and red (650 nm wavelength) stimuli. Hill of vision (HOV) analysis was performed on 2cDAP perimetry with Visual Field Modeling and Analysis (VFMA). Full field threshold stimulus testing (FST) was also measured as a secondary measure of rod-mediated function, and assessed on a Diagnosys Espion with the ColorDome stimulator (Diagnosys LLC). Eight eyes from 4 patients who were treated with voretigene bilaterally had rod function assessed by 2cDAP testing at least 1 year after treatment. There was statistically significant improvement in 2cDAP following gene augmentation therapy. HOV VFMA analysis showed widespread improvements that extended beyond the treatment bleb and statistically significant improvement in HOV analysis volumetric measurements post-treatment to cyan and red stimuli. FST testing performed in six eyes from three patients demonstrated statistically significant improvement to all chromatic stimuli following treatment. These findings demonstrated statistically significant improvement in 2cDAP and FST following treatment with voretigene. These findings provide a sensitive method of assessing rod-mediated function in a topographic manner that may be useful in future clinical trials for inherited retinal dystrophies.

Identifiants

pubmed: 37058101
pii: 2785536
doi: 10.1167/tvst.12.4.17
pmc: PMC10117223
doi:

Substances chimiques

retinoid isomerohydrolase EC 3.1.1.64

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Subventions

Organisme : NEI NIH HHS
ID : K08 EY026650
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States

Références

Ophthalmology. 1986 Dec;93(12):1604-11
pubmed: 3808619
Expert Opin Orphan Drugs. 2015 May 4;3(5):563-575
pubmed: 26246977
Ophthalmology. 2018 Nov;125(11):1765-1775
pubmed: 29884405
Orphanet J Rare Dis. 2020 Feb 14;15(1):49
pubmed: 32059734
Lancet. 2014 Oct 25;384(9953):1513-20
pubmed: 25030840
Transl Vis Sci Technol. 2017 Aug 09;6(4):15
pubmed: 28798898
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1122-1131
pubmed: 30901388
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6177-82
pubmed: 15837919
Invest Ophthalmol Vis Sci. 1979 Apr;18(4):426-9
pubmed: 311766
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1898-908
pubmed: 10845615
Br J Ophthalmol. 1983 Jul;67(7):405-18
pubmed: 6860608
Arch Ophthalmol. 1971 Dec;86(6):612-22
pubmed: 5316012
Ophthalmology. 2019 Sep;126(9):1273-1285
pubmed: 31443789
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3118-28
pubmed: 27304843
Am J Ophthalmol. 2021 Oct;230:123-133
pubmed: 33951446
Arch Ophthalmol. 2012 Jan;130(1):9-24
pubmed: 21911650
Invest Ophthalmol Vis Sci. 1979 Mar;18(3):263-72
pubmed: 422332
Am J Ophthalmol. 1947 Jun;30(6):705-20
pubmed: 20241735
Transl Vis Sci Technol. 2018 Nov 27;7(6):10
pubmed: 30510854
Doc Ophthalmol. 2009 Dec;119(3):217-24
pubmed: 19885692
N Engl J Med. 2015 May 14;372(20):1920-6
pubmed: 25936984
Br J Ophthalmol. 1985 May;69(5):326-39
pubmed: 3873253
Lancet. 2017 Aug 26;390(10097):849-860
pubmed: 28712537
Transl Vis Sci Technol. 2015 Apr 28;4(2):14
pubmed: 25938002
Transl Vis Sci Technol. 2020 Oct 08;9(11):9
pubmed: 33133772
N Engl J Med. 2008 May 22;358(21):2231-9
pubmed: 18441371
Ophthalmology. 2021 Oct;128(10):1460-1468
pubmed: 33798654

Auteurs

Cristy A Ku (CA)

Department of Ophthalmology, University of California Davis, Sacramento, CA, USA.

Austin D Igelman (AD)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Samuel J Huang (SJ)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Huber Vasconcelos (H)

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.

Mariana Matioli da Palma (MM)

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.

Steven T Bailey (ST)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Andreas K Lauer (AK)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Richard G Weleber (RG)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Paul Yang (P)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Mark E Pennesi (ME)

Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH